BMO Capital Markets initiated coverage on Novo Nordisk A/S with a new price target

4/12/24 7:34:01 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BMO Capital Markets initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $163.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVO

Date	Price Target	Rating	Analyst
4/17/2025	$64.00	Outperform → Market Perform	BMO Capital Markets
3/13/2025		Hold → Buy	Kepler
3/3/2025		Buy → Hold	Stifel
2/12/2025		Equal-Weight	Morgan Stanley
1/6/2025		Underperform → Mkt Perform	Bernstein
5/30/2024	$156.00	Buy	Goldman
4/12/2024	$163.00	Outperform	BMO Capital Markets
1/23/2024	$120.00	Overweight	Morgan Stanley